Compare Ascendis Pharma A/S (ASND) vs Impinj Inc (PI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Impinj Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Impinj Inc trades at $140.86 (market cap $4.39B). The key difference: Ascendis Pharma A/S is far larger — about 4× Impinj Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Impinj Inc nearer its low. Which is the better fit depends on your goals.
| ASND | PI | |
|---|---|---|
Market Cap | $17.74B | $4.39B |
Sector | Health | Technology |
52-Week High | $277.18 | $241.91 |
52-Week Low | $163.32 | $91.34 |
Enterprise Value | $18.11B | $4.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Impinj (PI) trades at $144.03, down 0.26% today, with a bullish technical signal supported by moving averages and a golden cross pattern. The company reported Q1 2026 earnings of $0.14 per share, beating estimates, but faces negative net income margins and high valuation multiples. Recent news highlights insider selling and upcoming Q2 2026 results, while analyst consensus remains strongly bullish with a $167.50 price target.
The outlook for PI is mixed: strong analyst support and technical momentum suggest upside potential, but profitability challenges and high valuations pose risks. Investment opportunity hinges on execution improving margins and revenue growth, while key risks include competitive pressures and insider selling trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
